Physician profile
Michael Williams
NPI 1790342426
$3,646.04
in general payments reported to CMS, 2019-2025
23 companies · $729 in 2025
The $729 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $476 · 2023: $996 · 2024: $742 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,465.36 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $418.10 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.45 | 2021-2025 | Relistor |
| Medtronic, INC. | $244.94 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $229.75 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Proclaim, Octrode |
| Redhill Biopharma INC. | $127.86 | 2021 | |
| Averitas Pharma INC. | $126.27 | 2023-2025 | Qutenza |
| Azurity Pharmaceuticals, INC. | $120.33 | 2023-2025 | Horizant, Horizant |
| Amgen INC. | $90.27 | 2021-2025 | Evenity, Prolia |
| Arbor Pharmaceuticals, INC. | $84.47 | 2021-2022 | |
| Grt US Holding, INC. | $66.06 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $56.59 | 2024-2025 | |
| Bioventus LLC | $40.37 | 2021-2022 | |
| Almatica Pharma LLC | $36.72 | 2021 | |
| Nevro Corp. | $34.62 | 2022-2024 | Senza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.08 | 2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $28.87 | 2023 | Zilretta, Iovera |
| Ibsa Pharma INC. | $21.28 | 2022 | |
| Valinor Pharma, LLC | $20.67 | 2025 | Movantik |
| Fidia Pharma USA INC. | $20.61 | 2023 | Hymovis |
| Merz Pharmaceuticals, LLC | $19.08 | 2024 | Xeomin |
| Acacia Pharma INC | $15.53 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.